866-997-4948(US-Canada Toll Free)

Metastatic Colorectal Cancer - Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Aug 2012

Category :

Cancer

No. of Pages : 576 Pages


Metastatic Colorectal Cancer Pipeline Review, H2 2012

Global Markets Directs, \'Metastatic Colorectal Cancer Pipeline Review, H2 2012\', provides an overview of the Metastatic Colorectal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer. \'Metastatic Colorectal Cancer Pipeline Review, H2 2012\' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Colorectal Cancer.
  • A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Colorectal Cancer pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Metastatic Colorectal Cancer therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Metastatic Colorectal Cancer Therapeutic Products under Development, Key Players in Metastatic Colorectal Cancer Therapeutics, Metastatic Colorectal Cancer Pipeline Overview, Metastatic Colorectal Cancer Pipeline, Metastatic Colorectal Cancer Pipeline Assessment
Table of Contents

Table of Contents 2

List of Tables 10
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Metastatic Colorectal Cancer Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Metastatic Colorectal Cancer 15
Metastatic Colorectal Cancer Therapeutics under Development by Companies 17
Metastatic Colorectal Cancer Therapeutics under Investigation by Universities/Institutes 22
Late Stage Products 28
Comparative Analysis 28
Mid Clinical Stage Products 29
Comparative Analysis 29
Early Clinical Stage Products 30
Comparative Analysis 30
Discovery and Pre-Clinical Stage Products 31
Comparative Analysis 31
Metastatic Colorectal Cancer Therapeutics Products under Development by Companies 32
Metastatic Colorectal Cancer Therapeutics Products under Investigation by Universities/Institutes 39
Companies Involved in Metastatic Colorectal Cancer Therapeutics Development 47
Bristol-Myers Squibb Company 47
Boehringer Ingelheim GmbH 48
F. Hoffmann-La Roche Ltd. 49
Kyowa Hakko Kirin Co., Ltd. 50
Amgen Inc. 51
Sanofi-Aventis 52
AstraZeneca PLC 53
Eli Lilly and Company 54
Genentech, Inc. 55
Daiichi Sankyo Company, Ltd 56
Merck & Co., Inc. 57
Biothera 89
AVEO Pharmaceuticals, Inc. 90
Cytavis Biopharma GmbH 91
Medical Enzymes AG 92
Therapure Biopharma Inc. 93
Oncozyme Pharma Inc. 94
Metastatic Colorectal Cancer Therapeutics Assessment 95
Assessment by Monotherapy Products 95
Assessment by Combination Products 96
Assessment by Route of Administration 97
Assessment by Molecule Type 99
Drug Profiles 102
Perifosine - Drug Profile 102
RG7414 - Drug Profile 105
Regorafenib - Drug Profile 106
DI17E6 - Drug Profile 108
IMC-A12 - Drug Profile 110
Fibromun - Drug Profile 111
Brostallicin - Drug Profile 113
RG3638 - Drug Profile 115
Selumetinib - Drug Profile 116
HyFIVE - Drug Profile 118
HA-Irinotecan - Drug Profile 119
LE-SN38 - Drug Profile 121
CetuGEX - Drug Profile 123
Sym004 - Drug Profile 124
Afinitor - Drug Profile 125
IMC-1121B - Drug Profile 128
JX-594 - Drug Profile 130
MM-398 - Drug Profile 131
MORAb-004 - Drug Profile 133
TAS102 - Drug Profile 134
Vectibix - Drug Profile 135
GlutaDON - Drug Profile 138
Aptocine - Drug Profile 140
Pentamidine - Drug Profile 142
SN-38 Liposome - Drug Profile 144
CY-503 - Drug Profile 145
Imprime PGG + Erbitux - Drug Profile 288
Irinotecan + Cetuximab - Drug Profile 289
Pemetrexed + Gemcitabine - Drug Profile 290
PEG-SN38 + Cetuximab - Drug Profile 291
Panitumumab + Xelox - Drug Profile 293
Xelox - Drug Profile 295
Avastin - Drug Profile 297
Cetuximab + Irinotecan - Drug Profile 298
FOLFIRI + Bevacizumab - Drug Profile 299
Ethyol + CPT-11 - Drug Profile 301
Bevacizumab + Xeloda - Drug Profile 303
Irinotecan + Oxaliplatin - Drug Profile 304
Erbitux + FOLFIRI - Drug Profile 305
Erbitux + FOLFOX - Drug Profile 307
Erbitux + FOLFOX - Drug Profile 309
Icrucumab + mFOLFOX6 - Drug Profile 311
FOLFIRI + Cetuximab + Bevacizumab - Drug Profile 313
Irinotecan + Capecitabine + Avastin - Drug Profile 315
Enzastaurin + Leucovorin + Fluorouracil + Bevacizumab - Drug Profile 316
FOLFIRI + Panitumumabbb - Drug Profile 318
Irinotecan + Panitumumab - Drug Profile 319
Irinotecan + Temsirolimus - Drug Profile 320
FOLFIRI - Drug Profile 321
Panitumumab + Rilotumumab - Drug Profile 323
Simvastatin + Panitumumab - Drug Profile 325
BMS 354825 - Drug Profile 327
Modified FOLFOX6 + Nexavar - Drug Profile 329
Sorafenib + FOLFIRI - Drug Profile 331
Xeloda - Drug Profile 333
S-1 + Leucovorin - Drug Profile 334
Bevacizumab + Capecitabine + Oxaliplatin - Drug Profile 360
Sorafenib + FOLFOX6 - Drug Profile 362
RO4929097 - Drug Profile 364
AMG 386 + FOLFIRI - Drug Profile 373
Avastin + Eloxatin + Xeloda + Tarceva - Drug Profile 375
FOLFIRI + Cetuximab - Drug Profile 377
SOX + Cetuximab - Drug Profile 378
AMG 479 + Panitumumab - Drug Profile 380
Cetuximab + TS-1 - Drug Profile 381
S-1 + Oxaliplatin + Bevacizumab - Drug Profile 382
S-1 + Leucovorin + Oxaliplatin + Bevacizumab - Drug Profile 384
FOLFIRI + Erbitux - Drug Profile 386
Cholecalciferol + FOLFOX + Bevacizumab - Drug Profile 387
Cetuximab + Simvastatin - Drug Profile 389
Sorafenib + Capecitabine - Drug Profile 390
Panitumumab + S-1 + Irinotecan - Drug Profile 391
Azacitidine + CAPOX - Drug Profile 392
Panitumumab + Irinotecan - Drug Profile 394
Panitumumab - Drug Profile 395
Gemcitabine + Capecitabine - Drug Profile 396
SOX - Drug Profile 397
TS-1 + Irinotecan + Bevacizumab - Drug Profile 398
Cetuximab + RO4929097 - Drug Profile 400
FOLFOX + Erbitux - Drug Profile 401
XELOX + Bevacizumab - Drug Profile 402
Capecitabine + Bevacizumab + Oxaliplatin - Drug Profile 418
Cetuximab + Folfri - Drug Profile 420
FOLFIRI - Drug Profile 422
ABT-888 + Capecitabine + Oxaliplatin - Drug Profile 424
CS-1008 + FOLFIRI - Drug Profile 426
Necitumumab + mFOLFOX-6 - Drug Profile 428
Cetuximab - Drug Profile 430
PX-866 + Erbitux - Drug Profile 431
Vidaza + Entinostat - Drug Profile 432
Zaltrap - Drug Profile 434
Cetuximab + 5-Fluorouracil + Leucovorin - Drug Profile 436
AZD6244 + Cetuximab - Drug Profile 437
RO4929097 + Capecitabine - Drug Profile 438
FOLFOXIRI - Drug Profile 440
FOLFIRI - Drug Profile 442
Xelox - Drug Profile 465
Aptocine + FOLFIRI - Drug Profile 466
Aptocine + FOLFOX4 - Drug Profile 468
TBI 302 - Drug Profile 470
Brivanib + Irinotecan - Drug Profile 471
Pentamidine + FOLFIRI - Drug Profile 472
JX-594 + Irinotecan - Drug Profile 474
TSU-68 + S-1 + Oxaliplatin - Drug Profile 476
ColoAd1 - Drug Profile 478
TS-1 + Oxaliplatin + Bevacizumab - Drug Profile 479
FOLFOX + MetMAb + Bevacizumab - Drug Profile 481
RG7414 + Bevacizumab + mFOLFOX6 - Drug Profile 483
Pentamidine + mFOLFOX6 - Drug Profile 485
Gemcitabine + UFT + Etoposide - Drug Profile 487
Actimab-C - Drug Profile 488
CMAB009 + Irinotecan - Drug Profile 489
BKM120 + LDE225 - Drug Profile 490
Irinotecan - Drug Profile 491
FOLFIRI - Drug Profile 493
capecitabine + celecoxib - Drug Profile 495
Metastatic Colorectal Cancer Therapeutics Drug Profile Updates 496
Metastatic Colorectal Cancer Therapeutics Discontinued Products 535
Metastatic Colorectal Cancer Therapeutics - Dormant Products 538
Metastatic Colorectal Cancer Product Development Milestones 547
Featured News & Press Releases 547

Appendix 558
Methodology 558
Coverage 558
Secondary Research 558
Primary Research 558
Expert Panel Validation 558
Contact Us 559
Disclaimer 559

List of Table


Number of Products Under Development for Metastatic Colorectal Cancer, H2 2012 32
Products under Development for Metastatic Colorectal Cancer Comparative Analysis, H2 2012 33
Number of Products under Development by Companies, H2 2012 35
Number of Products under Development by Companies, H2 2012 (Contd..1) 36
Number of Products under Development by Companies, H2 2012 (Contd..2) 37
Number of Products under Development by Companies, H2 2012 (Contd..3) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 44
Comparative Analysis by Late Stage Development, H2 2012 45
Comparative Analysis by Mid Clinical Stage Development, H2 2012 46
Comparative Analysis by Early Clinical Stage Development, H2 2012 47
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 48
Products under Development by Companies, H2 2012 49
Products under Development by Companies, H2 2012 (Contd..1) 50
Products under Development by Companies, H2 2012 (Contd..2) 51
Products under Development by Companies, H2 2012 (Contd..3) 52
Products under Development by Companies, H2 2012 (Contd..4) 53
Products under Development by Companies, H2 2012 (Contd..5) 54
Products under Development by Companies, H2 2012 (Contd..6) 55
Products under Investigation by Universities/Institutes, H2 2012 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 63
Bristol-Myers Squibb Company, H2 2012 64
Boehringer Ingelheim GmbH, H2 2012 65
F. Hoffmann-La Roche Ltd., H2 2012 66
Kyowa Hakko Kirin Co., Ltd., H2 2012 67
Amgen Inc., H2 2012 68
Sanofi-Aventis, H2 2012 69
AstraZeneca PLC, H2 2012 70
Eli Lilly and Company, H2 2012 71
Genentech, Inc., H2 2012 72
Daiichi Sankyo Company, Ltd, H2 2012 73
Merck & Co., Inc., H2 2012 74
Takeda Pharmaceutical Company Limited, H2 2012 75
Symphogen A/S, H2 2012 76
Light Sciences Oncology, Inc., H2 2012 77
Celltrion, Inc., H2 2012 78
Novartis AG, H2 2012 79
Pfizer Inc., H2 2012 80
Taiho Pharmaceutical Co., Ltd., H2 2012 81
Cell Therapeutics, Inc., H2 2012 82
Enzon Pharmaceuticals, Inc., H2 2012 83
Bayer AG, H2 2012 84
Merck KGaA, H2 2012 85
Novartis Pharmaceuticals Corporation, H2 2012 86
4SC AG, H2 2012 87
Alchemia Limited, H2 2012 88
AEterna Zentaris Inc., H2 2012 89
Idera Pharmaceuticals, Inc., H2 2012 90
Oncolytics Biotech Inc., H2 2012 91
Oncothyreon Inc, H2 2012 92
ARQULE, INC, H2 2012 93
Regeneron Pharmaceuticals, Inc., H2 2012 94
Morphotek, Inc., H2 2012 95
INSYS Therapeutics, Inc., H2 2012 96
Actinium Pharmaceuticals, Inc., H2 2012 97
Philogen S.p.A., H2 2012 98
Glycotope GmbH, H2 2012 99
Celator Pharmaceuticals, Inc., H2 2012 100
Merrimack Pharmaceuticals, Inc., H2 2012 101
Jennerex Biotherapeutics, Inc., H2 2012 102
MolMed S.p.A., H2 2012 103
Syndax Pharmaceuticals, Inc., H2 2012 104
Globeimmune, Inc., H2 2012 105
Biothera, H2 2012 106
AVEO Pharmaceuticals, Inc., H2 2012 107
Cytavis Biopharma GmbH, H2 2012 108
Medical Enzymes AG, H2 2012 109
Therapure Biopharma Inc., H2 2012 110
Oncozyme Pharma Inc., H2 2012 111
Assessment by Monotherapy Products, H2 2012 112
Assessment by Combination Products, H2 2012 113
Assessment by Stage and Route of Administration, H2 2012 115
Assessment by Stage and Molecule Type, H2 2012 118
Metastatic Colorectal Cancer Therapeutics Drug Profile Updates 513
Metastatic Colorectal Cancer Therapeutics Discontinued Products 552
Metastatic Colorectal Cancer Therapeutics Discontinued Products (Contd..1) 553
Metastatic Colorectal Cancer Therapeutics Discontinued Products (Contd..2) 554
Metastatic Colorectal Cancer Therapeutics Dormant Products 555
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..1) 556
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..2) 557
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..3) 558
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..4) 559
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..5) 560
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..6) 561
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..7) 562
Metastatic Colorectal Cancer Therapeutics Dormant Products (Contd..8) 563

List of Chart


Number of Products under Development for Metastatic Colorectal Cancer, H2 2012 32
Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Investigation by Universities/Institutes, H2 2012 39
Late Stage Products, H2 2012 45
Mid Clinical Stage Products, H2 2012 46
Early Clinical Stage Products, H2 2012 47
Discovery and Pre-Clinical Stage Products, H2 2012 48
Assessment by Monotherapy Products, H2 2012 112
Assessment by Combination Products, H2 2012 113
Assessment by Route of Administration, H2 2012 114
Assessment by Stage and Route of Administration, H2 2012 115
Assessment by Molecule Type, H2 2012 116
Assessment by Stage and Molecule Type, H2 2012 117

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *